Dainippon reports encouraging results from Phase III bipolar depression drug.
In: PharmaWatch: CNS, Jg. 11 (2012-06-01), Heft 6, S. 23-24
report
Zugriff:
The article reports on the results of the Phase III clinical trials conducted by Dainippon Sumitomo Pharma Co. Ltd., which examine the efficacy and safety of Latuda as an adjunctive therapy and monotherapy in patients with bipolar I depression . It notes that Latuda has shown statistically significant improvements in the patients' symptoms of depression. It mentions the common adverse events of Latuda including nausea, headache, and somnolence.
Titel: |
Dainippon reports encouraging results from Phase III bipolar depression drug.
|
---|---|
Zeitschrift: | PharmaWatch: CNS, Jg. 11 (2012-06-01), Heft 6, S. 23-24 |
Veröffentlichung: | 2012 |
Medientyp: | report |
Schlagwort: |
|
Sonstiges: |
|